Characteristics of patients who responded to imatinib mesylate
| Patient . | Age, y (sex) . | Disease status . | Prior salvage therapy . | Time from DLI to imatinib mesylate, mo . | Time from SCT to imatinib mesylate therapy, mo . | Imatinib mesylate dose, mg . | Response to imatinib mesylate . | Best CG response, lowest Ph+ . | Response duration, mo . | Survival, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 43 (M) | ACC/CE | None | — | 23 | 600 | CG CR | 0 | 3+ | 9+ |
| 2 | 25 (M) | ACC/CE | IFN | — | 68 | 600 | CG PR | 10 | 6+ | 12+ |
| 3 | 58 (F) | ACC/CE | IFN | — | 26 | 1000 | CG PR | 11 | 15+ | 23+ |
| 4 | 46 (M) | ACC/CE+PLT | IFN/other | — | 32 | 600 | CG CR | 0 | 12+ | 15+ |
| 5 | 52 (F) | ACC/CE+PLT | None | — | 14 | 600 | CG CR | 0 | 13+ | 16+ |
| 6 | 37 (M) | ACC/PLT | Multiple SCT | — | 15 | 400 | CG CR | 0 | 6 | 8 |
| 7 | 43 (F) | ACC/CE+PLT | DLI/other | 4 | 35 | 600 | HI | 7 | 13+ | |
| 8 | 43 (F) | ACC/CE/CHR | DLI/IFN | 4 | 32 | 600 | CG CR | 0 | 9+ | 12+ |
| 9 | 35 (M) | ACC/CE | DLI | 3 | 31 | 600 | CG PR | 5 | 5+ | 10+ |
| 10 | 28 (M) | ACC/CE | DLI/IFN | 22 | 87 | 600 | CG CR | 0 | 15+ | 18+ |
| 11 | 58 (M) | ACC/CE | DLI | 4 | 28 | 1000 | CG CR | 0 | 22+ | 23+ |
| 12 | 41 (F) | ACC/CE+BLAST | DLI | 26 | 113 | 600 | CG CR | 0 | 11+ | 24+ |
| 13 | 46 (F) | BP | None | — | 5 | 800 | HI | 2 | 9 | |
| 14 | 46 (F) | BP | None | — | 3 | 500 | CG PR | 20 | 1.5 | 2 |
| 15 | 51 (M) | BP | DLI | 2 | 140 | 600 | CG CR | 0 | 9+ | 19+ |
| 16 | 32 (M) | BP | DLI/other | 2 | 52 | 400 | CG PR | 20 | 1 | 9 |
| 17 | 48 (F) | BP-EMD | DLI | 7 | 14 | 750 | CR | 0 | 8 | 22+ |
| 18 | 51 (M) | Chronic | None | — | 13 | 400 | CHR | 17+ | 18+ | |
| 19 | 52 (F) | Chronic | None | — | 52 | 400 | CHR | 14+ | 15+ | |
| 20* | 34 (M) | Chronic/CHR; Ph 0% PCR+ | Other | — | 11 | 1000 | CG CR, PCR− | 0 | 17+ | 17+ |
| 21 | 60 (M) | Chronic | IFN/DLI | 8 | 10 | 600 | CHR | 8+ | 9+ | |
| 22 | 64 (F) | Chronic | DLI/IFN | 39 | 105 | 800 | CG PR | 24 | 17+ | 23+ |
| Patient . | Age, y (sex) . | Disease status . | Prior salvage therapy . | Time from DLI to imatinib mesylate, mo . | Time from SCT to imatinib mesylate therapy, mo . | Imatinib mesylate dose, mg . | Response to imatinib mesylate . | Best CG response, lowest Ph+ . | Response duration, mo . | Survival, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 43 (M) | ACC/CE | None | — | 23 | 600 | CG CR | 0 | 3+ | 9+ |
| 2 | 25 (M) | ACC/CE | IFN | — | 68 | 600 | CG PR | 10 | 6+ | 12+ |
| 3 | 58 (F) | ACC/CE | IFN | — | 26 | 1000 | CG PR | 11 | 15+ | 23+ |
| 4 | 46 (M) | ACC/CE+PLT | IFN/other | — | 32 | 600 | CG CR | 0 | 12+ | 15+ |
| 5 | 52 (F) | ACC/CE+PLT | None | — | 14 | 600 | CG CR | 0 | 13+ | 16+ |
| 6 | 37 (M) | ACC/PLT | Multiple SCT | — | 15 | 400 | CG CR | 0 | 6 | 8 |
| 7 | 43 (F) | ACC/CE+PLT | DLI/other | 4 | 35 | 600 | HI | 7 | 13+ | |
| 8 | 43 (F) | ACC/CE/CHR | DLI/IFN | 4 | 32 | 600 | CG CR | 0 | 9+ | 12+ |
| 9 | 35 (M) | ACC/CE | DLI | 3 | 31 | 600 | CG PR | 5 | 5+ | 10+ |
| 10 | 28 (M) | ACC/CE | DLI/IFN | 22 | 87 | 600 | CG CR | 0 | 15+ | 18+ |
| 11 | 58 (M) | ACC/CE | DLI | 4 | 28 | 1000 | CG CR | 0 | 22+ | 23+ |
| 12 | 41 (F) | ACC/CE+BLAST | DLI | 26 | 113 | 600 | CG CR | 0 | 11+ | 24+ |
| 13 | 46 (F) | BP | None | — | 5 | 800 | HI | 2 | 9 | |
| 14 | 46 (F) | BP | None | — | 3 | 500 | CG PR | 20 | 1.5 | 2 |
| 15 | 51 (M) | BP | DLI | 2 | 140 | 600 | CG CR | 0 | 9+ | 19+ |
| 16 | 32 (M) | BP | DLI/other | 2 | 52 | 400 | CG PR | 20 | 1 | 9 |
| 17 | 48 (F) | BP-EMD | DLI | 7 | 14 | 750 | CR | 0 | 8 | 22+ |
| 18 | 51 (M) | Chronic | None | — | 13 | 400 | CHR | 17+ | 18+ | |
| 19 | 52 (F) | Chronic | None | — | 52 | 400 | CHR | 14+ | 15+ | |
| 20* | 34 (M) | Chronic/CHR; Ph 0% PCR+ | Other | — | 11 | 1000 | CG CR, PCR− | 0 | 17+ | 17+ |
| 21 | 60 (M) | Chronic | IFN/DLI | 8 | 10 | 600 | CHR | 8+ | 9+ | |
| 22 | 64 (F) | Chronic | DLI/IFN | 39 | 105 | 800 | CG PR | 24 | 17+ | 23+ |
IFN indicates interferon; ACC, accelerated; CE, clonal evolution; BP, blastic phase; EMD, extramedullary disease; CG CR, cytogenetic complete response; CG PR, cytogenetic partial response; CG minor, cytogenetic minor response; HI, hematologic improvement; ACC CE, accelerated phase based on clonal evolution alone; ACC CE + BLAST, accelerated phase based on clonal evolution + increased blasts > 15%; ACC-PLT, accelerated phase based on thrombocytopenia; ACC/CE/CHR, accelerated phase based on clonal evolution, but normal WBC count.
0% Ph-positive cells by fluorescent in situ hybridization.